Fractalkin and cardiovascular disease

Cover Page

Cite item

Full Text

Abstract

Fractalkine (or chemokine CX3CL1) belongs to the chemokine family and is a protein with a molecular weight of 95 kDa, is considered as a marker of endothelial dysfunction. According to the available data of modern studies, fractalkine can be positioned as a marker of the activity of inflammatory processes of different genesis; as an important prognostic indicator in chronic heart failure of both ischemic and non-ischemic etiology and a marker for monitoring the effectiveness of the treatment in this group of patients; as a predictor of adverse outcomes and an indicator of the effectiveness of percutaneous coronary intervention in patients with acute myocardial infarction, a valuable prognostic marker for patients with stable angina (with hemodynamically significant stenosis of the coronary arteries), as well as a predictor of thrombotic and thromboembolic complications in atrial fibrillation. Currently, it is a highly promising to study drug effects on fractalkine (CX3CL1) and its receptor (CX3CR1) for the pathogenetic treatment of cardiovascular diseases. Key words: fractalkine, atherosclerotic cardiovascular diseases, chronic heart failure, acute myocardial infarction, left ventricle. For citation: Alieva A.M., Almazova I.I., Pinchuk T.V. et al. Fractalkin and cardiovascular disease. Consilium Medicum. 2020; 22 (5): 83-86. DOI: 10.26442/20751753.2020.5.200186

About the authors

Amina M. Alieva

Pirogov Russian National Research Medical University

Email: amisha_alieva@mail.ru
канд. мед. наук, доц. каф. госпитальной терапии №2 лечебного фак-та

Ilda I. Almazova

National Medical Research Center for Therapy and Preventive Medicine

канд. мед. наук, врач-преподаватель

Tatiana V. Pinchuk

Pirogov Russian National Research Medical University

канд. мед. наук, доц. каф. факультетской терапии педиатрического фак-та

Elena V. Reznik

Pirogov Russian National Research Medical University

д-р мед. наук, проф. каф. госпитальной терапии №2 лечебного фак-та

Alik M. Rakhaev

Main Bureau of Medical and Social Expertise in the Kabardino-Balkarian Republic

д-р мед. наук, рук. экспертного состава

Igor G. Nikitin

Pirogov Russian National Research Medical University

д-р мед. наук, проф., зав. каф. госпитальной терапии №2 лечебного фак-та

References

  1. Cherepanov D, Bentley TGK, Hsiao W et al. Real-world Cardiovascular Disease Burden in Patients With Atherosclerotic Cardiovascular Disease: A Comprehensive Systematic Literature Review. Curr Med Res Opin 2018; 34 (3): 459-73. doi: 10.1080/03007995.2017.1401529
  2. Guo Y, Apostalakis S, Blann AD, Lip GYH. Plasma CX3CL1 Levels and Long-Term Outcomes of Patients with Atrial Fibrillation: The West Birmingham Atrial Fibrillation Project. Cerebrovasc Dis 2014; 38 (3): 204-11. doi: 10.1159/000365841
  3. Кухтина Н.Б., Арефьева Т.И., Рулева Н.Ю. и др. Пептидные фрагменты хемокинового домена фракталкина: влияние на миграцию моноцитов человека. Биоорганич. химия. 2012; 38 (6): 660-6.
  4. Garton KJ, Gough PJ, Blobel CP et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276: 37993-8001. ИНФОРМАЦИЯ ОБ АВТОРАХ / INFORMATION ABOUT THE AUTHORS
  5. Hildemann SK, Schulz C, Fraccarollo D et al. Fractalkine Promotes Platelet Activation and Vascular Dysfunction in Congestive Heart Failure. Thromb Haemost 2014; 111 (4): 725-35. doi: 10.1160/TH13-08-0640
  6. Skoda M, Stangret A, Szukiewicz D. Fractalkine and Placental Growth Factor: A Duet of Inflammation and Angiogenesis in Cardiovascular Disorders. Cytokine Growth Factor Rev 2018; 39: 116-23. doi: 10.1016/j.cytogfr.2017.12.001
  7. Mizutani N, Sakurai T, Shibata T et al. Dose-dependent differential regulation of cytokine secretion from macrophages by Fractalkine. J Immunol 2007; 179 (11): 7478-87.
  8. Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004; 11: 15-21.
  9. Schulz C, Schafer A, Stolla M et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764-73.
  10. Liu H, Jiang D, Zhang S, Ou B. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010; 24: 17-24.
  11. Ji CL, Nomi A, Li B et al. Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance. Int Heart J 2019; 60 (3): 701-7. doi: 10.1536/ihj.18-422
  12. Butoi ED, Gan AM, Manduteanu I et al. Cross talk between smooth muscle cells and monocytes/ac-tivated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta 2011; 1813: 2026-35.
  13. Apostolakis S, Spandidos D. Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin 2013; 34: 1251-6.
  14. Zhou JJ, Wang YM, Lee VWS et al. DEC205-DC Targeted DNA Vaccine Against CX3CR1 Protects Against Atherogenesis in Mice. PLoS One 2018; 13 (4): e0195657. doi: 10.1371/journal.pone.0195657
  15. Stolla M, Pelisek J, von Brohl ML et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS ONE 2012; 7: e43572.
  16. Li J, Guo Y, Luan X et al. Independent roles of monocyte chemoattractant protein-1, regulated on activation, normal T-cell expressed and secreted and fractalkine in the vulnerability of coronary atherosclerotic plaques. Circ J 2012; 76: 2167-73.
  17. Richter B, Koller L, Hohensinner PJ et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 2012; 108: 1220-7.
  18. Patel A, Jagadesham VP, Porter KE et al. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease. Eur J Vasc Endovasc Surg 2008; 36: 20-7.
  19. Rius C, Company C, Piqueras L et al. Critical role of fractalkine (CX3CL1) in cigarette smoke-induced mononuclear cell adhesion to the arterial endothelium. Thorax 2013; 68: 177-86.
  20. Wanling Xuan, Yulin Liao, Baihe Chen et al. Detrimental Effect of Fractalkine on Myocardial Ischaemia and Heart Failure. Cardiovasc Res 2011; 92 (3): 385-93. doi: 10.1093/cvr/cvr221
  21. Полунина Е.А., Воронина Л.П., Севостьянова И.В. и др. Уровень фракталкина при хронической сердечной недостаточности различной степени тяжести. Кардиология. 2018; 58 (8S): 54-7. doi: 10.18087/cardio.2473
  22. Лопина Н.А., Журавлева Л.В. Уровни фракталкина и асимметричного диметиларгинина у больных ишемической болезнью сердца в зависимости от наличия сахарного диабета 2-го типа и характера поражения коронарных артерий. Научный результат. Медицина и фармация. 2016; 2 (3): 11-7.
  23. Yao K, Zhang S, Lu H et al. Changes in fractalkine in patients with ST-elevation myocardial infarction. Coronary Artery Disease 2015; 26 (6): 516-20. doi: 10.1097/MCA.0000000000000273

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).